GlassScriptPhysician profile
Richard B Kasdan
NPI 1598761025
$172,019.77
in general payments reported to CMS, 2019-2025
58 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76K · 2020: $31K · 2021: $33K · 2022: $26K · 2023: $3,470 · 2024: $1,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,105 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,105.48 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $66,244.42 | 2019-2023 | |
| Emd Serono, INC. | $39,615.41 | 2019-2023 | Mavenclad |
| Acorda Therapeutics, INC | $34,243.02 | 2019-2024 | Inbrija |
| Biogen, INC. | $15,369.42 | 2019-2024 | Tysabri, Tysabri |
| Novartis Pharmaceuticals Corporation | $1,510.81 | 2019-2024 | |
| Abbvie INC. | $1,396.01 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $1,149.62 | 2019-2024 | Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $933.01 | 2019-2024 | Nuplazid |
| Ucb, INC. | $917.28 | 2019-2023 | Briviact |
| Alexion Pharmaceuticals, INC. | $788.56 | 2019-2023 | Ultomiris, Soliris |
| Neurocrine Biosciences, INC. | $740.11 | 2020-2024 | Ingrezza, Ongentys |
| Avanir Pharmaceuticals, INC. | $613.91 | 2019-2022 | |
| Neurelis, INC. | $608.13 | 2020-2023 | Valtoco |
| Mdd US Operations, LLC | $579.22 | 2019-2024 | Gocovri, Gocovri, Apokyn |
| Genentech USA, INC. | $557.30 | 2019-2024 | Ocrevus, Enspryng |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Kasdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.